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Objective: The aim of this study was to evaluate the effects of an oligoantigenic and histamine-free diet on
patients affected with chronic idiopathic urticaria (CIU).
Design: Ten patients with chronic idiopathic urticaria were prescribed an oligoantigenic and histamine-free diet
for 21 days, followed by serial and controlled reintroduction of foods during a further 70 days. Modification in
clinical illness as well as histamine plasma levels, post-heparin plasma diamine oxidase (DAO) and intestinal
permeability were evaluated.
Results: The oligoantigenic and histamine-free diet induced a significant improvement of symptoms (P< 0.05).
Moreover, CIU patients on free diet showed higher histamine plasma levels (P< 0.05 vs post-diet and vs
controls) that fell to control levels during the oligoantigenic and histamine-free diet. Post-heparin plasma
diamine oxidase values were slightly reduced and were unchanged during the diet as well as intestinal
permeability, which was always normal in all patients.
Conclusions: These data suggest that histamine plays a major role in chronic idiopathic urticaria. The finding of
normal intestinal permeability suggests that a morphological damage of intestinal mucosa should be excluded in
these patients. However, the presence of low levels of post-heparin plasma diamine oxidase may indicate a
subclinical impairment of small bowel enterocyte function that could induce a higher sensitivity to histamine-
rich or histamine-producing food.
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Introduction
Urticarias are a complex group of disorders characterised
by itchy wheals or swelling of the skin. In 70 – 95% of
patients the cause of chronic urticaria remains undeter-
mined. Chronic idiopathic urticaria (CIU) is defined as
repeated episodes or even continuous urticaria of unknown
origin (Champion, 1988; Kaplan, 1988) and without any
evidence if IgE mediated reaction (Warin, 1976). About
30 – 40% of patients with chronic urticaria attribute their
symptoms to food intolerance (Julin, 1981; Sayag et al,
1988), even if the affected person is seldom able to exactly
identify the causative food. The possible pathogenic role of
pseudoallergic reactions to food has been repeatedly dis-
cussed. The term ‘pseudo food allergy’ is usually used for
reactions involving histamine or mast cell degranulation as
a mechanism in which the primary stimulus is non-
immunologic (i.e. not IgE mediated; Smith et al, 1995;
Barlow et al, 1995; Bischoff et al, 1992; Claveau et al,
1993; Zweiman et al, 1998).
Mast cells are considered the primary effector cells in
urticaria. The typical symptoms can be attributed to the
effect of histamine and other mast cell mediators on local
tissue constituents. It has been suggested that pseudoallergic
manifestations are not only the result of mast cell activa-
tion, but also a consequence of a defect in histamine
metabolism (Lessof, 1991). Histamine is metabolized by
two pathways, oxidation and methylation. N-methyl trans-
ferase methylases histamine in the skin and is active in the
liver. Diamine oxidase (DAO) normally degrades hista-
mine, methyl histamine and diamine and it is confined to
the small bowel mucosa. The loss of the protective role of
mucosal DAO might allow an increased absorption of
biological amines.
In the past few years, several reports on the usefulness of
the plasma post-heparin diamine oxidase (PHD) test in
evaluating the small intestinal mucosa integrity have been
published (D’Agostino et al, 1987a, b; Corazza et al, 1988;
Thompson et al, 1988). The test is based on the ability of
heparin to release the enzyme diamine oxidase (DAO) from
the small intestinal mucosa into the circulation (Shakir
et al, 1977; D’Agostino et al, 1989). Since the enzyme is
synthesized by the differentiated and non-proliferating
enterocytes, the enzyme activity in the blood after an
intravenous injection of heparin correlates with the mor-
phologic integrity of the small intestinal epithelium
(D’Agostino et al, 1987a, b; Luk et al, 1983). The test
proved to be helpful in quantitating the remaining mature
enterocyte mass in patients with celiac disease, before
(D’Agostino et al, 1987b; Corazza et al, 1988) and after
(D’Agostino et al, 1987b) gluten-free diet, small bowel
lymphoma (Salmeron & Modigliani, 1984) and Crohn’s
disease (D’Agostino et al, 1988; Thompson et al, 1988).
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It has been suggested that the non-immunological forms
of urticaria may be triggered by increased absorption or
impaired metabolism of mediators such as histamine
(Lessof, 1991). The aim of the present study was to
evaluate histamine plasma levels as well as post-heparin
DAO and intestinal permeability in patients with idiopathic
chronic urticaria before and after an oligoallergenic diet.
Methods
We enrolled 10 patients (mean age 31.7 y, s.d. 12.7; three
men and seven women) with chronic idiopathic urticaria
not controlled by therapy (steroids, H1 anti-histamines
and=or diet). Clinical manifestations of disease were pom-
phus, itch and angioedema. All patients, before starting the
study, were on a free and uncontrolled diet. No patient
complained of gastrointestinal symptoms. We evaluated
post-heparin plasma DAO activity, jejunal mucosal perme-
ability and histamine plasma levels before and after a
oligoantigenic and histamine-free diet. Diagnosis of CIU
was defined according to the criteria of Warin (1976).
Before entering the study, all patients were evaluated by
prick skin tests for common food allergens and only
negative patients were enrolled. Patients did not take any
medication for 20 days before and during the study. Each
patient was prescribed an individual restricted diet for 21
days and continued serial reintroduction for the following
70 days. Diet was normocaloric (according to RDA guide-
lines) and the proportion of carbohydrate, fat, and protein
was 55 – 60%, 25 – 30%, and 15 – 20% respectively.
Patients were evaluated before starting the diet, after 21
days of controlled diet and thereafter at days 60 and 90.
The control group for plasma levels histamine determin-
ations included six healthy subjects. Informed consent was
obtained from all patients and approval for the study was
obtained from the university’s standing committee on
ethical practice.
Diet
Dietary procedures consisted of two different steps:
1. A 3 week period with a oligoantigenic (Metcalfe, 1984;
Bahna, 1984) and histamine-free diet (Wantke, 1993).
During this period the patients made a daily assessment
of their symptoms by filling in a diary card and reporting
symptoms. Symptoms (pomphus, itching, angioedema)
were each scored daily using a numerical scale of
severity (0, 1, 2, 3) in order of increasing severity.
2. A 10 week run-in period with a serial reintroduction of
individual foods in normal amounts every other day.
Foods were introduced according to antigenic character-
istics of animals and vegetables (Sheldon et al, 1967).
During this period the patients continued to fill in the daily
diary symptom score. Whenever a patient identified an
offending food, this was eliminated from the diet and
tested again at the end of the period, in order to make a
definite diagnosis of intolerance. The well-tolerated foods
were introduced in the patient’s diet.
Plasma histamine assay
Blood was drawn in each patient, after an overnight fast, at
about 8.30 a.m. Samples were immediately centrifuged at
4C (1000 rpm for 10 min) and plasma was separated from
blood cells. Proteins were precipitated by the addition of
10% perchloric acid and supernatant was stored at 7 20C.
Histamine assay was performed in one run with an auto-
mated fluorometric technique (Siragarian, 1974; Patella et
al, 1995a, b).
PHD test and DAO assay
Heparin (15 000 I.U.) was administered by an intravenous
bolus. Blood (7 ml) was drawn 60 min after the injection,
collected in heparinized tubes, and centrifuged at 3000 g.
Plasma was stored at 7 20C and assayed for DAO within
a week. Written informed consent was obtained from all
patients. No complication resulted from the heparin bolus.
Whenever the test was performed in outpatients, they were
allowed to leave the hospital 4 h after the end of the test.
DAO was assayed in triplicate by a 14C-putrescine method
as described in a previous study. Briefly, the assay mixture
contained: 1.5 ml sodium phosphate buffer, 0.1 M, pH 7.2;
0.3 ml sample; and 0.1 ml substrate, a mixture of putrescine
dihydrochloride and 1-4 14C-putrescine dihydrochloride up
to a final concentration of 5 nmol per tube with an activity
of 0.1 mCi. The samples were incubated for 60 min at 37C.
The labeled reaction product, 14C-1-pyridine, was directly
extracted in a toluene-based scintillation mixture and
assayed for 14C by a Packard Tricarb 4530 scintillation
counter (Okuyama and Kobayashi, 1961). DAO activity
was expressed as U=ml (1 U 1 nmol of putrescine dihy-
drochloride oxidised in 1 h at 37C pH 7.2). Based on
previous studies, the normal range was considered to be
3.7 – 7.7 U=ml (D’Agostino et al, 1988).
Intestinal permeability
Intestinal permeability was evaluated by the cellobiose=
mannitol sugar permeability test, as described by Strobel et
al (1984). After an overnight fast, patients presented at about
8.30 a.m. Patients emptied the bladder and then drank a
solution containing 5 g cellobiose, 2 g mannitol and 20 g
sucrose, diluted in 200 ml sterile water. Urine was collected
during the following 5 h. After recording the total urine
volume, 10 ml aliquots were stored at 7 20C for cellobiose
and mannitol assay. Mannitol was assayed by the methods of
Corcoran and Page (1974). It was oxidized to formaldehyde
by periodic acid. Formaldehyde reacts with chromotropic
acid to form a purple complex which is measured at 570 nm
absorbance. Cellobiose was assayed by the method described
by Strobel et al (1984). Cellobiose reacts with b-glucosidase
to yield two molecules of glucose. D-Glucose was measured
using the hexochinase procedure with NADPH generation
measured at 340 nm. For each of the two administered
molecules cellobiose and mannitol, the percentage urinary
recovery was calculated. The final ratio of percentage cello-
biose recovery to percentage mannitol recovery (C=M ratio)
was calculated. A C=M ratio lower than 3761073 was
considered normal (Strobel et al, 1984).
Data were expressed as the mean s.d. Statistical ana-
lysis was performed by Student’s t-test.
Results
The baseline patient characteristics are listed in Table 1. In
all patients symptoms were greatly reduced after 3 weeks
on the diet and continued to improve thereafter. Figure 1
shows the response to the dietary protocol.
Follow-up at 13 weeks showed complete remission in
3=10, partial remission in 3=10 and partial remission with
transient relapses in 4=10. Patients in the latter group
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showed transient relapses that appeared to be correlated to
emotion or intercurrent illnesses.
Histamine plasma levels in patients with CIU were
significantly (P< 0.05) higher than controls and were
significantly reduced after 21 days of the diet (P< 0.05;
Figure 2).
Table 2 shows post-heparin DAO activity and intestinal
permeability before and after 21 days of a controlled diet.
Post-heparin DAO activity was slightly reduced or close to
the lower limit of the normal range. Small intestinal
permeability appeared normal in all patients. Neither
DAO activity nor intestinal permeability showed any sig-
nificant modification after diet.
Discussion
In chronic idiopathic urticaria the possible pathogenic role
of pseudoallergic reactions to food has been repeatedly
discussed, but stringent prospective studies regarding their
clinical significance are not available. An alternative patho-
genic mechanism hypothesized (Lessof, 1991) is a reduc-
tion of the intestinal barrier against chemical compounds,
such as histamine, contained in some foods that may trigger
pseudoallergic reactions. In fact, many patients suffering
from CIU attribute their symptoms to food intolerance
(Julin, 1981; Sayag et al, 1988; Bischoff & Manns, 1998).
Increased levels of skin histamine have been reported in
patients with CIU (Smith et al, 1995) while, to our know-
ledge, histamine plasma levels have not been previously
evaluated.
In the present study we found higher histamine plasma
levels in CIU patients on free diet compared to controls.
After an oligoantigenic and histamine-free diet, plasma
histamine levels fell to the same levels of the control
group. This finding suggests that histamine plasma levels
are dependent on diet in patients with chronic idiopathic
urticaria.
Both an oligoantigenic and histamine-free diet (Wantke,
1993; Metcalfe, 1984) and an additive- and preservative-
free diet (Zuberbier et al, 1995; Henz & Zuberbier, 1998)
have been shown to induce significant clinical improve-
ment in patients with CIU. In our study, the disappearance
or reduction of symptoms after the diet appeared to be
correlated with lower histamine plasma levels.
A deficient degradation of histamine by the enzyme
diamine oxidase has been hypothesized as a possible
cause of an increased absorption of histamine (Lessof,
1991). In our study, post-heparin DAO levels in CIU
patients were slightly reduced compared to controls or in
the lower part of the normal range. This observation may
suggest a subclinical impairment of small bowel enterocyte
function that can allow a higher absorption of histamine
and higher histamine plasma levels. However, no signifi-
cant modification of post-heparin DAO was found after an
effective oligoantigenic and histamine-free diet, while a
significant clinical improvement was recorded. A possible
explanation to this discrepancy is that the diet improved
symptoms only be reducing histamine load to the small
bowel but did not after the functional status of intestinal
mucosa. However, the reason for relatively low DAO levels
remains unexplained and will need further studies to be
clarified.
Gastrointestinal permeability was normal in CIU
patients and was not changed after the diet. This observa-
tion indicates that a morphological damage of intestinal
mucosa should be excluded in CIU. In the present study,
Table 1 Baseline characteristics of subjects
Characteristics Data
All subjects (n) 10
Age (y s.d.) 31.7 12.7
Male (n) 3
Female (n) 7
Duration of symptoms (months) 14.5 (7 – 60)a
Subjects with pomphus (n) 10
Subjects with itching (n) 10
Subjects with angioedema (n) 9
aMedian; lower and upper values in parentheses.
Figure 1 Post treatment improvement of symptoms. Values recorded
before starting the diet for itching, pomphus and edema (pre diet) were
significantly higher (P< 0.05) than values observed after an oligoantigenic
and histamine-free diet (after 21 days) and during serial controlled
reintroduction of foods (after 60 days and after 90 days).
Figure 2 Histamine plasma levels in subjects with CIU vefore and after
diet and in controls. Histamine plasma levels in patients with CIU were
significantly (P< 0.05) higher than in controls and were significantly
reduced after 21 days of diet (P< 0.05).
Table 2 DAO activity and intestinal permeability index at baseline and
after the diet. Compared to normal values, post-heparin DAO activity
was slightly reduced, while intestinal permeability was normal. Both
parameters were not affected by the diet
Value
Pre-dieta Post-dieta Normal values
DAO (U=ml) s.d. 2.79 1.56 2.90 1.22 > 3.7
Permeability Index
C=M(%)6103 s.d. 13.04 3.5 17.35 3.5 < 3.7
aAfter 21 days of diet.
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the avoidance of the offending food(s) followed by a serial
reintroduction of a ‘low histamine’ diet appeared to be
effective to improve symptoms and reduce histamine
plasma levels.
However, we can not establish whether clinical
improvement was due to low levels of histamine or low
levels of offending antigens in the diet. Furthermore,
whether the low histamine plasma levels are caused by
the reduced exogenous load or by a fall in mast cell
histamine production remains unclear.
In conclusion, this study suggests that pseudo-allergic
manifestations of CIU may be related to a subclinical
functional impairment of the small bowel. This condition
may result in a loss of the protective role of the intestinal
mucosa against offending molecules in foods. While an
increased histamine absorption caused by a reduction of
small bowel DAO activity might be one of such mechan-
isms, we can not exclude a role for other chemical food
compounds. Further studies are needed to better elucidate
the pathogenic mechanisms of CIU and to evaluate the
possible effects of foods on mast cell degranulation.
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